MOBI Mobia Medical, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1489993 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA—
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets12.8%
Debt / equity0.05x
Current ratio11.79x
Interest coverage—
Cash quality & payout
Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $15.62M | $13.51M | $12.07M | $9.01M | $6.67M | $5.66M |
| Cost of revenue | $2.62M | $2.27M | $2.13M | $1.84M | $1.18M | $1.01M |
| Gross profit | $13.00M | $11.24M | $9.94M | $7.18M | $5.49M | $4.65M |
| R&D expense | $2.55M | $2.28M | $1.69M | $1.60M | $1.42M | $1.35M |
| SG&A expense | $28.98M | $26.89M | $25.19M | $16.83M | $14.53M | $13.60M |
| Operating income | -$18.53M | -$17.93M | -$16.94M | -$11.26M | -$10.46M | -$10.30M |
| Interest expense | $257,000 | $254,000 | $357,000 | $244,000 | $241,000 | $239,000 |
| Pretax income | -$17.34M | -$21.04M | -$17.74M | -$11.42M | -$10.49M | -$10.65M |
| Income tax | $2,000 | $2,000 | $0 | $1,000 | $2,000 | $1,000 |
| Net income | -$17.34M | -$21.04M | -$17.74M | -$11.42M | -$10.49M | -$10.65M |
| EBITDA | -$18.35M | -$17.83M | -$16.88M | -$11.22M | -$10.43M | -$10.27M |
| EPS (basic) | -0.52 | -1.10 | -19.30 | -13.31 | -12.44 | -12.97 |
| EPS (diluted) | -0.52 | -1.10 | -19.30 | -13.31 | -12.44 | -12.97 |
| Weighted avg. shares (diluted) | 33.30M | 19.09M | 918,935 | 858,354 | 843,168 | 821,160 |
| Balance sheet | ||||||
| Cash & equivalents | $160.69M | $177.09M | $55.73M | — | — | — |
| Receivables | $7.00M | $5.66M | $4.85M | — | — | — |
| Inventory | $8.35M | $6.95M | $6.05M | — | — | — |
| Current assets | $178.22M | $192.15M | $71.71M | — | — | — |
| PP&E, net | $1.94M | $2.06M | $738,000 | — | — | — |
| Total assets | $181.17M | $195.28M | $73.60M | — | — | — |
| Current liabilities | $15.12M | $14.47M | $11.83M | — | — | — |
| Long-term debt | $7.30M | $7.28M | $7.26M | — | — | — |
| Total debt | $7.30M | $7.28M | $7.26M | — | — | — |
| Total liabilities | $23.26M | $22.68M | $61.57M | — | — | — |
| Shareholders' equity | $157.91M | $172.61M | -$167.75M | -$137.33M | -$126.35M | -$116.28M |
| Net debt | -$153.39M | -$169.81M | -$48.47M | — | — | — |
| Shares outstanding | 33.33M | 33.29M | 1.00M | — | — | — |
| Cash flow statement | ||||||
| Operating cash flow | -$12.92M | -$15.67M | -$17.73M | -$11.59M | -$11.00M | -$9.72M |
| Capital expenditure | $58,000 | $1.54M | $42,000 | $236,000 | $0 | $23,000 |
| Free cash flow | -$12.98M | -$17.21M | -$17.77M | -$11.83M | -$11.00M | -$9.75M |
| Investing cash flow | -$58,000 | -$1.54M | -$42,000 | -$236,000 | $0 | -$23,000 |
| Financing cash flow | -$3.42M | $138.57M | $39.91M | $37,000 | $11,000 | $32.42M |
| Depreciation & amortization | $177,000 | $100,000 | $56,000 | $39,000 | $32,000 | $31,000 |
| Stock-based compensation | $2.56M | $1.61M | $407,000 | $406,000 | $404,000 | $201,000 |
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.